New guidelines show better outcomes for managing hematological malignancies in pregnancy

News
Video

Discover updated strategies for treating leukemia and lymphomas during pregnancy, emphasizing delayed delivery, chemotherapy safety, and multidisciplinary care for optimal maternal and fetal health.

In a recent interview with Contemporary OB/GYN, Giselle Kidson-Gerber, MD, a hematologist with expertise in obstetric hematology, shared insights into new guidelines for managing hematological malignancies during pregnancy, specifically acute leukemia and aggressive lymphomas.

These conditions pose significant risks to maternal and fetal health, but advancements in management provide hope for better outcomes. Acute leukemia is life-threatening if untreated, with symptoms such as anemia, infection, and bleeding, although it is often detected through routine blood work during pregnancy. Aggressive lymphomas, on the other hand, may present with masses in the neck, chest, or abdomen, often identified through obstetric ultrasounds, or symptoms such as shortness of breath, fevers, or night sweats.

The guidelines emphasize the importance of delaying birth to optimize fetal neurocognitive development. Evidence shows that gestational age at delivery has a greater impact on long-term outcomes than in utero exposure to chemotherapy. Women diagnosed in the second or early third trimester are encouraged to undergo chemotherapy during pregnancy rather than opting for early delivery. PET scans, critical for diagnosing and monitoring lymphomas, are now considered safe during pregnancy when proper modeling of fetal radiation exposure is conducted. The guidelines also address breastfeeding and include data on the limited use of newer treatment agents during pregnancy.

A multidisciplinary approach is essential for managing these complex cases. Collaboration among maternal-fetal medicine specialists, obstetricians, hematologists, midwives, nurses, and allied health professionals ensures comprehensive care. Effective communication, seamless coordination, and detailed documentation are critical, especially in settings where hospital services may be physically separated. The guidelines stress the importance of creating a written management plan covering all trimesters, delivery, and postpartum care to guide both patients and health care teams.

The key clinical takeaways focus on avoiding premature decisions such as early termination or delivery, involving a multidisciplinary team, and reassuring patients that positive outcomes are achievable. Kitson-Gerber highlighted that most women with hematological malignancies can be treated effectively during pregnancy and encouraged health care providers to consult the guidelines for evidence-based strategies. With expert support and collaborative care, health care teams can help ensure favorable outcomes for both mother and child in these high-risk scenarios.

Recent Videos
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Ivie Odiase, MD
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Laxmi Gannu, MD, notes PPD screening gaps and adverse outcomes | Image Credit: linkedin.com.
Farah Amro, MD
Laurence Shields, MD, is System Physician Vice President at the Women and Infants Clinical Institute with CommonSpirit Health in Santa Maria, California.
Joy Baker, MD, FACOG, highlights how to recognize PPD | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.